Cidara Therapeutics — Investor Day (September 2021)
110 slides from Cidara Therapeutics's investor day presentation, Sep 21, 2021
Slide 1: Cidara R&D Day Sept 21st 2021
1 C I D A R A R & D D AY S E P T 2 1 s t 2 0 2 1
Slide 2: Forward-Looking Statements
2 F O R WA R D - LO O K I N G S TAT E M E N T S T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 . The words “believe,” “may,” “will,” “e
Slide 3: Program Overview
3 P R O G R A M O V E R V I E W : J E F F R E Y S T E I N , P H D , C E O Taylor Sandison, CMOClinical Program Update REZAFUNGIN Hematology Expert ID/Fungal Expert Mark Levis, Johns Hopkins Kieren Marr, Johns Hopkins Les Tari, CSO CLOUDBREAK Eric Simoes, Univ. of Colorado Commercial Update Paul Daru
Slide 4: Cidara Investment Thesis
4 C I D A R A I N V E S T M E N T T H E S I S L e a d i n g s c i e n c e o n l o n g - a c t i n g a n t i f u n g a l a n d a n t i v i r a l p r e v e n t i o n a n d t r e a t m e n t REZAFUNGIN 1st antifungal in 15 years for treatment and prophylaxis indications Treatment – Phase 3 Prophylaxis
Slide 5: Up to $1.3B potential value from existing partnerships
5 U P TO $ 1 . 3 B I N P OT E N T I A L VA LU E F R O M E X I S T I N G PA R T N E RS H I P S • $30M upfront • $9M equity investment • $42M in development support • $487M clin/reg/comm milestones • Double-digit royalties in the teens Program: Rezafungin | Rights: ex-US/Japan $568M P h a s e 2 d a t
Slide 6: Rezafungin Update
6 REZAFUNGIN UPDATE S E P T E M B E R 2 0 2 1
Slide 7: Global antifungal market and unmet need
7 Source: Global sales for Cancidas – IQVIA; Noxafil – 2018 Merck Annual Report. Antifungal market data from IQVIA, as of December 31, 2017. GLOBAL ANTIFUNGAL MARKET $ 4 . 2 B I L L I O N NO NEW CANDIDA TREATMENT NO NEW PROPHYLAXIS 1 5 Y E A R V O I D HIGH MORTALITY DRUG-DRUG INTERACTIONS C L E A R
Slide 8: Rezafungin Clinical Program
8 R E Z A F U N G I N C L I N I C A L P R O G R A M TAY LO R S A N D I S O N , M D C H I E F M E D I C A L O F F I C E R , C I D A R A
Slide 9: Two pivotal studies for treatment and prophylaxis
9 T W O P I V OTA L S T U D I E S F O R T R E AT M E N T A N D P R O P H Y L A X I S TARGET INDICATION Treatment of candidemia and invasive candidiasis Prophylaxis against Aspergillus, Candida & Pneumocystis in allogeneic blood and marrow transplant patients P H A S E 3 P R O P H Y L A X I S T R I A
Slide 10: Two pivotal studies for treatment and prophylaxis
10 T W O P I V OTA L S T U D I E S F O R T R E AT M E N T A N D P R O P H Y L A X I S P H A S E 3 T R E A T M E N T T R I A L 1 TARGET INDICATION OVERALL OBJECTIVE Treatment of candidemia and invasive candidiasis FDA: Day 30 All-cause mortality vs SOC Expect topline data by end of 2021 TRIAL SIZE 18
Slide 11: STRIVE Phase 2 program overview
11 S T R I V E P H A S E 2 P R O G R A M O V E RV I E W • The Intent-to-treat (ITT) population: all randomized subjects • The Safety population: all subjects who received any amount of study drug • The Microbiological Intent-to-treat population (mITT): all subjects in safety population who had docum
Slide 12: Rezafungin Phase 2 efficacy and safety
12 R E Z A F U N G I N P H A S E 2 M E T I T S E F F I C A C Y A N D S A F E T Y O B J E C T I V E S Not powered for non-inferiority Comparable efficacy and safety to 1st line agent Superior time to negative blood culture Trends to improved early outcomes 1. STRIVE Phase 2: CID September, 2020. 1
Slide 13: Day 30 all-cause mortality post hoc analysis
13 3 0 - D AY A L L C A U S E M O R TA L I T Y – P O S T H O C A N A LY S I S F R O M P H A S E 2 S U P E R I O R I T Y N O N - I N F E R I O R I T Y 0-20% 10%-10% F A V O R S R E Z A F U N G I N FA V O R S C A S P O F U N G I N ReSTORE Phase 3 trial endpoint requires upper limit of confidence inter
Slide 14: STRIVE Phase 2 time to negative blood culture
14 S T R I V E P H A S E 2 T I M E T O N E G AT I V E B L O O D C U LT U R E 1 , 2 P H A S E 2 : A D D I T I O N A L B E N E F I T S M AY B E D U E TO F R O N T - LO A D E D D O S I N G O n c e w e e k l y f r o n t - l o a d e d d o s e e r a d i c a t e d f u n g i e a r l i e r t h a n c a s p o
Slide 15: Additional benefits may be due to front-loaded dosing
15 0 5 10 15Days REZAFUNGIN 400/200 % Neg. Blood Culture1 % Overall Cure2 Average Days in ICU1 CASPOFUNGINRz Cf2 Rz Cf Rz Cf 5 ICU DAYS 28/38 1 DAY 5 DAYS 2 DAYS 27/50 31/36 32/49 34/46 34/61 % Neg. Blood Culture2 73.7 54.0 73.9 55.7 86.1 65.3 13 DAYS 18 DAYS n/N n/N n/N P H A S E 2 : A D D I T I O
Slide 16: ReSTORE Phase 3 program overview
16 Re S TO R E P H A S E 3 P R O G R A M O V E RV I E W • The Intent-to-treat (ITT) population: all randomized subjects • The Safety population: all subjects who received any amount of study drug • The Microbiological Intent-to-treat population (mITT): all subjects in safety population who had docum
Slide 17: Rezafungin Treatment Prophylaxis
17 Rezafungin Rezafungin — Treatment — Prophylaxis
Slide 18: ReSPECT prophylaxis trial may enable new standard of care
18 R e S P E C T P H A S E 3 P R O P H Y L A X I S T R I A L M AY E N A B L E N E W S TA N D A R D O F C A R E P H A S E 3 T R E A T M E N T T R I A L 1 TARGET INDICATION TRIAL SIZE Treatment of candidemia and invasive candidiasis 184 patients3 (20% noninferiority margin) FDA: Day 30 All-cause morta
Slide 19: Rezafungin designed to simplify prophylaxis dosing regimen
19 R E Z A F U N G I N : D E S I G N E D TO S I M P L I F Y P R O P H Y L A X I S D O S I N G R E G I M E N A n t i f u n g a l p r o p h y l a x i s i n a l l o g e n e i c b l o o d a n d m a r r o w t r a n s p l a n t s e t t i n g 1 , 2 SOC for Candida and Aspergillus Day 8070605040302010-10 0
Slide 20: ReSPECT may enable rezafungin to replace 3 drugs
20 Week 1 2 3 4 12 Azole placebo Bactrim placebo Rezafungin 5 13 Day 1 17 90 120 1° Endpoint: Fungal Free Survival at Day 902 Follow upREZAFUNGIN ARM (N=~300) 17Week 1 2 3 4 12 Azole1 Bactrim Rezafungin Placebo 5 13 Day 1 90 120 COMPARATOR ARM (N=~150) Dose Includes patients with: AML, MDS, ALL, CML
Slide 21: Unmet need in prevention of invasive fungal disease
21 U N M E T N E E D I N P R E V E N T I O N O F I N VA S I V E F U N G A L D I S E A S E I N C A N C E R A N D T R A N S P L A N T PAT I E N T S M A R K L E V I S , M D A N D K I E R E N M A R R , M D J O H N S H O P K I N S U N I V E R S I T Y
Slide 22: Hematologist viewpoint: management of AML
Hematologist Viewpoint - Setting up the problem Management of AML MARK LEVIS, MD P R O G R A M L E A D E R , H E M A T O L O G I C M A L I G N A N C I E S A N D B O N E M A R R O W T R A N S P L A N T P R O G R A M , S I D N E Y K I M M E L C O M P R E H E N S I V E C A N C E R C E N T E R P R O F E
Slide 23: AML incidence and mortality rates
AML Incidence and Mortality Rates 20,240 new cases/year • Compare with lung cancer: 235,760 cases/year 11,400 deaths/year • Compare with lung cancer: 131,880 deaths/year Source: CA CANCER J CLIN 2021; 71:7–33 AML in the US: AML at Hopkins: 23
Slide 24: AML is frequently a medical emergency
AML is frequently a medical emergency… Patients routinely present with: o Low platelets, leading to risk of catastrophic bleeding o Low hemoglobin, causing physical exhaustion o Low white blood cells, leading to rapidly fatal infections Best management is to quickly treat the disease into remiss
Slide 25: AML at Johns Hopkins Kimmel Cancer Center
AML at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 180 patients admitted each year to the Adult Leukemia Service o All newly-diagnosed (typically transferred from an ER…) o Majority undergo immediate therapy • 50% intensive, 50% non-intensive o Hospital stay of 2-6 weeks • 130 a
Slide 26: Typical AML patient treatment course
Diagnosis, Transfer to leukemia service Months 0 1 2 3 4 5 6 7 8 9 Induction Consolidation Consolidation Bone marrow transplant “Induce” a remission The “Typical” AML patient treatment course 26
Slide 27: What if someone doesn't get treated
What if someone doesn’t get treated…? 27
Slide 28: 7+3 intensive induction therapy for AML
Cytarabine o 100 or 200 mg/m2/day CI for 7 days Anthracycline o 45-90 mg/m2 dauno or 12 mg/m2 ida IVP Days 1-3 Day 14 marrow… o If aplasia (marrow < 5% cellularity), wait for recovery o If residual leukemia, give 5+2 starting Day 21. o If after counts are recovered and still residual leukemia,
Slide 29: Azacitidine + venetoclax non-intensive induction
Fast forward to present day… Azacitidine + venetoclax: A non-intensive induction Source: N Engl J Med 2020; 383:617-629 29
Slide 30: Preventing invasive fungal infections: risks and needs
ID & Hematologist Facing a team dilemma Preventing Invasive Fungal Infections: Risks and Needs KIEREN MARR MD MBA P RO F ES S O R O F M E D I C I N E , J O H N S H O P K I N S S C H O O L O F M E D I C I N E D I R EC TO R , T R A N S P L A N T A N D O N CO LO GY I N F EC T I O U S D I S EA S ES V I
Slide 31: Antifungal prophylaxis needed
Antifungal prophylaxis needed candidiasis, aspergillosis, PCP Source: Atkins and He. Infect Dis Clin N Am 33 (2019) Infectious risk of treatment regimens by disease 31 Antifungal prophylaxis needed candidiasis, aspergillosis, PCP
Slide 32: AML patients benefit from posaconazole
AML patients receiving intensive chemotherapy benefit from posaconazole Posaconazole versus Fluconazole or Itraconazole for AML patients Source: Cornely et al N Engl J Med 2007 356:348-59 32
Slide 33: Venetoclax induction in AML
Venetoclax induction in AML Venetoclax-based induction is now used in at least 50% of AML cases Venetoclax is metabolized by the liver P450 system (CYP3A4) Other drugs inhibiting CYP3A4 will lead to higher levels of venetoclax, causing toxicity But underdosing venetoclax may lead to treatmen
Slide 34: Azoles: limited utility with new drugs
Azoles: Limited utility with new drugs Drug Company Effect Recommendations with Azoles Ibrutinib (Imbruvica) J&J AbbVie ↑ Ibrutinib exposure 12-100% of original dose Idelalisib Zydelig) Gilead ↑ AUC Monitor for side effects Acalabrutinib (Calquence) AZ ↑ acalabrutinib exposure Avoid combo Imatinib (
Slide 35: Back to the patient
Diagnosis, Transfer to leukemia service Months 0 1 2 3 4 5 6 7 8 9 Induction Consolidation Consolidation Bone marrow transplant Currently – we’re giving IV echinocandins on and off during periods of neutropenia With diagnosed IFI – we have to hold or dose-reduce anti-AML therapy (bad outcomes) Back
Slide 36: What do we need?
What do we need? Antifungal with activity against Candida and Aspergillus Not cytochrome P450 metabolized (few or no drug interactions) Able to administer o If daily, needs to be IV and oral o If longer half life, can be IV (weekly infusions enabled) Few or no toxicities (a must for preventa
Slide 37: Results of RezaHemeDDI study
37 R E S U LT S O F ‘ R E Z A H E M E ’ D D I S T U D Y TAY LO R S A N D I S O N , M D C H I E F M E D I C A L O F F I C E R , C I D A R A
Slide 38: No dose adjustment of venetoclax expected with rezafungin
38 N O D O S E A D J U S T M E N T O F V E N E TO C L A X E X P E C T E D W I T H R E Z A F U N G I N 0 50 100 150 200 250 300 0 10 20 30 40 50 60 70 80 Venetoclax alone Venetoclax with rezafungin Time (hours) Venetoclax concentration over time Hematologists reduce dose of venetoclax up to 88% if co
Slide 39: No dose adjustment of ibrutinib expected with rezafungin
39 N O D O S E A D J U S T M E N T O F I B R U T I N I B E X P E C T E D W I T H R E Z A F U N G I N 0 30 60 90 0 10 20 30 40 50 60 Ibrutinib alone Ibrutinib with rezafungin M ea n co nc en tr at io n (n g/ m L) Time (hours) Ibrutinib concentration over time1 Hematologists reduce dose of ibrutinib u
Slide 40: Rezafungin commercial value
40 R E Z A F U N G I N C O M M E R C I A L V A L U E P A U L D A R U W A L A C H I E F O P E R A T I N G O F F I C E R , C I D A R A
Slide 41: Azole DDI dilemma/opportunity and market potential
41 Rezafungin Rezafungin Azole DDI Dilemma/Opportunity Market Potential
Slide 42: The azole dilemma is both clinical and commercial
42 T H E A Z O L E D I L E M M A I S B OT H C L I N I C A L A N D C O M M E R C I A L Contraindications with azoles often require dose reduction of oncology therapy by 50-88%1, to levels not well studied Pipeline 2 AML ALL CLL Phase 1 197 141 115 Phase 2 186 153 86 Phase 3 24 8 9 Dose reductions mea
Slide 43: Two essential hematology drugs: Imbruvica and Venclexta
43 T W O E S S E N T I A L H E M ATO LO GY D R U G S : I M B R U V I C A & V E N C L E X TA * Global Data (2020 – actuals; 2021-2027 – analyst consensus forecast) $- $3,000 $6,000 $9,000 $12,000 $15,000 $18,000 2020 2021 2022 2023 2024 2025 2026 2027 Actual and Forecast Global Sales ($M)* >$15B Venc
Slide 44: Two essential hematology drugs: Imbruvica and Venclexta
44 T W O E S S E N T I A L H E M ATO LO GY D R U G S : I M B R U V I C A & V E N C L E X TA * Global Data (2020 – actuals; 2021-2027 – analyst consensus forecast) $- $3,000 $6,000 $9,000 $12,000 $15,000 $18,000 2020 2021 2022 2023 2024 2025 2026 2027 Actual and Forecast Global Sales ($M)* >$15B Venc
Slide 45: Azole DDI dilemma/opportunity and market potential
45 Rezafungin Rezafungin Azole DDI Dilemma/Opportunity Market Potential
Slide 46: Clear potential advantages of rezafungin
46 T H E R E A R E C L E A R P OT E N T I A L A D VA N TA G E S O F R E Z A F U N G I N E A R LY D I S C H A R G E / O U T PAT I E N T P O T E N T I A L YES Reza O N C E W E E K LY / F R O N T L O A D E D D O S I N G YES Daily Echinocandins NO NO
Slide 47: Current estimates assume ReSTORE meets 20% NI margin
47 C U R R E N T E S T I M AT E S A S S U M E Re S TO R E M E E T S 2 0 % N I M A R G I N Revenue Time Candida Treatment Infectious Disease Focus BASE CASE: ReSTORE meets 20% NI margin
Slide 48: Rezafungin targeted downstream for Candida treatment
48 R E Z A F U N G I N TA R G E T E D D O W N S T R E A M F O R C A N D I D A T R E AT M E N T Inpatient (1.6M pts/1.9M treatments) Daily IV Candin Daily IV Candin Rezafungin 29K 1.5% share example 5th YEAR FORECAST Patient and market share examples provided here are based on internal management ass
Slide 49: Rezafungin targeted downstream for Candida treatment
49 R E Z A F U N G I N T A R G E T E D D O W N S T R E A M F O R C A N D I D A T R E A T M E N T Inpatient (1.6M pts/1.9M treatments) Daily IV Candin Daily IV Candin Rezafungin 29K 1.5% share example 5th YEAR FORECAST PATIENTS • Stable • Azole non-susceptible • Early discharge possible PAYOR • Medic
Slide 50: Rezafungin targeted downstream for Candida treatment
50 R E Z A F U N G I N T A R G E T E D D O W N S T R E A M F O R C A N D I D A T R E A T M E N T Inpatient (1.6M pts/1.9M treatments) Outpatient (640K pts) Daily IV Candin Rezafungin Rezafungin Daily IV Candin Rezafungin 29K 9K 16K 3.9% share example1.5% share example 36% continuation of RZF from in
Slide 51: U.S. sample revenue build and key assumptions
51 U . S . S A M P L E R E V E N U E B U I L D A N D K E Y A S S U M P T I O N S F O R R E Z A F U N G I N Overall Treatment Inpatient Outpatient • Launch Treatment: 1Q23 • Launch Prophylaxis: 1H24 • No serious warnings/precautions • 30-50 reps, 6-8MSLs, 5 account managers • Focus on high AF & high
Slide 52: ReSTORE upsides enhance probability of faster uptake
52 Re S TO R E U P S I D E S E N H A N C E P R O B A B I L I T Y O F FA S T E R U P TA K E Revenue Time Candida Treatment Infectious Disease Focus Upside Case ReSTORE ~ STRIVE (Shorter ICU stay) Upside Plus Case Superiority BASE CASE: ReSTORE meets 20% NI margin
Slide 53: Clear potential advantages of rezafungin
53 T H E R E A R E C L E A R P OT E N T I A L A D VA N TA G E S O F R E Z A F U N G I N Well-tolerated No DDIs Fluconazole Posaconazole S A F E T Y / T O L E R A B I L I T Y Daily IV administration Hepatic and renal precautions Significant DDIs C O V E R A G E / S P E C T R U M Candida, Aspergillus
Slide 54: U.S. sample revenue build for rezafungin
54 U. S . S A M P L E R E V E N U E B U I L D F O R R E Z A F U N G I N *Prophylaxis revenue includes potential for product use other than in the anticipated initial indication, not supported by Company promotion. Overall Treatment Inpatient Outpatient 331 743 101 202 92 191 5-Year ($M) 10-Year ($M)
Slide 55: Other antifungals triangulate rezafungin market opportunity
55 OT H E R A N T I F U N G A L S T R I A N G U L AT E R E Z A F U N G I N M A R K E T O P P O R T U N I T Y *Prophylaxis revenue includes potential for product use other than in the anticipated initial indication, not supported by Company promotion. Overall Treatment Inpatient Outpatient 331 743 10
Slide 56: Cloudbreak Update
56 CLOUDBREAK UPDATE S E P T E M B E R 2 0 2 1
Slide 57: Cloudbreak has advantages over vaccines and treatments
57 57 C LO U D B R E A K H A S A D VA N TA G E S O V E R VA C C I N E S A N D T R E AT M E N T S MODERNA Sept 9, R&D Day report COVID-19 and flu combination vaccine REGENERON Sept 15, Endpoints News $2.9B purchase of COVID-19 antibodies (3rd supply deal)
Slide 58: Cloudbreak drug-Fc conjugates: a new class of drug
58 C L O U D B R E A K D R U G - F c C O N J U G A T E S : A N E W C L A S S O F D R U G L E S T A R I , P h D C H I E F S C I E N T I F I C O F F I C E R , C I D A R A
Slide 59: Cloudbreak combines an Fc moiety with potent antivirals
59 C LO U D B R E A K ® C O M B I N E S A N Fc M O I E T Y W I T H P OT E N T A N T I V I R A L S Fc MOIETY SM TARGETING MOIETIES PEPTIDE FUSIONS Extends PK and recruits immune system Single or multiple types of small molecules with direct antiviral activity can be conjugated to the same Fc Multiple
Slide 60: Cloudbreak is a new class of drug Fc conjugates
60 C LO U D B R E A K ® I S A N E W C L A S S O F D R U G F C C O N J U G AT E S : “ D F C s ” Drug Fc Conjugate
Slide 61: Unique advantages of drug-Fc-conjugates
61 U N I Q U E A D VA N TA G E S O F D R U G - Fc - C O N J U G AT E S VIRUS ADVANTAGES OF DFCs • Multivalent binding increases potency • Engaging different targets on the same virus improves spectrum, decreases resistance • Enables a single DFC to target multiple viruses
Slide 62: DFCs can be effective where current flu vaccines fall short
62 D F C s C A N B E E F F E C T I V E I N T H O S E M I S S E D BY C U R R E N T F LU VA C C I N E S 1. DFC assessments are based on pre-clinical study results and estimates Universal protection: multiple viruses Potential to protect all high risk groups Potential for prevention and treatment Scale
Slide 63: DFCs have potential advantages over antibodies
63 D F C s H A V E P O T E N T I A L A D V A N T A G E S O V E R A N T I B O D I E S 1. DFC assessments are based on pre-clinical study results and estimates Able to target cryptic sites, small molecule binding pockets Able to modulate drug-Fc-ratio to increase potency Able to install 2 or more disc
Slide 64: DFCs have potential advantages over small molecules
64 D F C s H AV E P OT E N T I A L A D VA N TA G E S O V E R S M A L L M O L E C U L E S 1. DFC assessments are based on pre-clinical study results and estimates 2. CYP450s, metabolic enzymes Selectivity vs host targets (toxicity potential) Pharmacokinetic properties, DDIs Distribution to compartmen
Slide 65: DFC development candidates targeting influenza
65 Single dose / ̴3 months Wild-type Fc (full immune engagement) C D 3 7 7 C D 3 8 8 Single dose / ̴4-6 months Mutant Fc (attenuated immune engagement, improved PK, and extended duration of action) D F C D E V E LO P M E N T C A N D I D AT E S TA R G E T I N G I N F LU E N Z A These are the first ag
Slide 66: DFCs have rapid distribution to lung
66 66 D F C s H A V E R A P I D D I S T R I B U T I O N T O L U N G CD377 concentration in plasma and Epithelial Lining Fluid (ELF) after a single 20 mg/kg subcutaneous dose Plasma Lung ELF C D 3 7 7 I N F LU E N Z A P R O G R A M CD377 concentration in lung epithelial lining fluid is ~ 60% of that
Slide 67: 28-day single-dose protection in mouse
67 67 2 8 - D A Y , S I N G L E - D O S E P R O T E C T I O N I N M O U S E A/Hong Kong/1/68 H3N2 SC dose Infect Vehicle Levin et al, IDWeek 2020, Abstract 159. 5 BALB/c mice per cohort C D 3 7 7 I N F L U E N Z A P R O G R A M CD377 is fully protective for 28-days in a lethal influenza model with a
Slide 68: DFCs show similar efficacy in immune competent and compromised mice
68 5 mice per cohort. CD377 (SC) dosing was initiated 2 hours post-infection CD377 – 0.1mg/kg Vehicle CD377 – 0.1mg/kg Vehicle A/PR/8/1934 H1N1 Mouse treatment models BALB/c immune competent SCID immune deficient D F C s S H O W S I M I L A R E F F I C A C Y I N I M M U N E C O M P E T E N T A N D C
Slide 69: Robust preclinical safety
69 R O B U S T P R E C L I N I C A L S A F E T Y 1. Results of 14-day preclinical toxicity testing, CD377 THERAPEUTIC MARGIN 0 250000 500000 Primate Area under the curve (AUC) for maximum dose tested (hr*mg/mL) Predicted AUC required for efficacy in humans (hr*mg/mL) 95x Clinical Observations Hemato
Slide 70: Unmet needs in respiratory viruses
70 U N M E T N E E D S I N R E S P I R ATO R Y V I R U S E S E R I C S I M O E S , M D U N I V E R S I T Y O F C O LO R A D O
Slide 71: Viral respiratory tract infections: prevention and treatment
Viral Respiratory Tract infect ions I m p o r t a n c e a n d P r o s p e c t s fo r P r e v e n t i o n a n d Tr e a t m e n t Eric A.F. Simões, Professor of Pediatrics Section of Infectious Diseases, University of Colorado School of Medicine, and Childrenʼs Hospital Colorado Professor of Epidemiol
Slide 72: Major viral respiratory pathogens
72 M A J O R V I R A L R E S P I R A T O R Y P A T H O G E N S 72 SARS CoV2 Influenza Virus Respiratory Syncytial Virus Rhinovirus Parainfluenza viruses Human Metapneumovirus
Slide 73: Major viral respiratory pathogens
73 M A J O R V I R A L R E S P I R A T O R Y P A T H O G E N S 73 SARS CoV2 Influenza Virus Respiratory Syncytial Virus Rhinovirus Parainfluenza viruses Human Metapneumovirus
Slide 74: SARS-CoV-2 global situation Sept 2021
74 S A RS C O V - 2 : G LO B A L S I T UAT I O N - 1 3 S E P T 2 0 2 1 https://covid19.who.int/ Accessed 13 Sept 2021 224 Million Confirmed Cases, 4.63 Million confirmed Deaths 5.4 Billion Vaccine Doses Administered 74
Slide 75: SARS-CoV-2 vaccines: good enough?
75 S A R S C O V 2 V A C C I N E S : M A N Y , B U T A R E T H E Y G O O D E N O U G H ? Huang H-Yet al., Hum Vaccin Immunother2021;17:3276-3280 75 442 Clinical Trials on 185 vaccine Candidates
Slide 76: Unmet needs in prevention and treatment persist
76 D E S P I T E AVA I L A B I L I T Y O F VA C C I N E S , U N M E T N E E D S I N P R E V E N T I O N A N D T R E AT M E N T S T I L L P R E S I D E Prevention Issues Treatment Issues • While efficacious vaccines are available, universal global distribution is a real issue. • Vaccines protect agai
Slide 77: Influenza: large pipeline of vaccine candidates
77 I N F LU E N Z A – L A R G E P I P E L I N E O F VA C C I N E C A N D I D AT E S https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm Accessed 10 Sept 21 Universal Protection is Still Elusive 77
Slide 78: Seasonal flu vaccine effectiveness is still sub-optimal
78 S E A S O N A L F LU VA C C I N E E F F E C T I V E N E S S I S S T I L L S U B - O P T I M A L https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm Accessed 10 Sept 21 … and even less effective for elderly and immune compromised 78
Slide 79: Universal influenza prevention is still a major unmet need
79 U N I V E RS A L I N F LU E N Z A P R E V E N T I O N I S S T I L L A M A J O R U N M E T N E E D Adult Subjects Pediatric Subjects Prevention Available Available Not very effective Not very effective Annual vaccination Annual vaccination through life Decreasing Efficacy Decreasing Efficacy 79
Slide 80: RSV prevention: still a challenging problem
80 RS V P R E V E N T I O N – S T I L L A C H A L L E N G I N G P R O B L E M VACCINES Still unproven and immunogenicity remains a problem mAbs Expensive, large dose (adults) Coverage/Resistance issues 80
Slide 81: Unmet needs in RSV prevention and treatment
81 U N M E T N E E D S I N R S V P R E V E N T I O N A N D T R E A T M E N T Prevention Issues Treatment Issues • For Infants Greatest burden of illness before 3 -6 months of age • Long acting monoclonal antibodies show promise but escape mutants are a possibility • Maternal immunization shows promi
Slide 82: Expanding outside of ID: RSV, HIV, SARS-CoV-2
82 RSV HIV SARS-CoV-2 Others — Improved potency — Broader coverage — Unique modality — Expanding outside of ID
Slide 83: Influenza provides validation to address additional indications
83 1 SC/IM dose/season Pan Flu Poor vaccines Pandemic Preparation FLU Janssen Pharmaceuticals I N F L U E N Z A P R O V I D E S VA L I D AT I O N TO A D D R E S S A D D I T I O N A L I N D I C AT I O N S RSV Seasonal Prevent | Treat 1 SC/IM dose/season No vaccine No Good Treatment HIV Chronic Mainta
Slide 84: Expanding outside of ID: RSV, HIV, SARS-CoV-2
84 RSV HIV SARS-CoV-2 Others — Improved potency — Broader coverage — Unique modality — Expanding outside of ID
Slide 85: RSV cases on the rise in wake of surging COVID cases
85 R S V C A S E S O N T H E R I S E I N T H E W A K E O F S U R G I N G C O V I D C A S E S AUGUST 14, 2021 • Leading cause of viral-induced infant mortality globally • No vaccines • Current therapies are suboptimal • New approaches clearly needed
Slide 86: The power of single molecule DFC cocktails
86 T H E P O W E R O F S I N G L E M O L E C U L E D F C C O C K TA I L S RVC-A RVC-B RVC-C 650 EC50 (nM) 0.2 EC50 (nM) <0.001 EC50 (nM) 4.0 EC50 (nM) RSV A2 Growth Inhibition Single molecule cocktail
Slide 87: The power of optimizing small molecules
87 T H E P O W E R O F O P T I M I Z I N G S M A L L M O L E C U L E S RSV A2 Growth Inhibition RVC-D 0.013 EC50 (nM) RVC-E 0.093 EC50 (nM) RVC-F 0.050 EC50 (nM) RVC-B 0.2 EC50 (nM)
Slide 88: The power of optimizing small molecules
88 T H E P O W E R O F O P T I M I Z I N G S M A L L M O L E C U L E S RSV A2 Growth Inhibition RVC-D 0.013 EC50 (nM) RVC-E 0.093 EC50 (nM) RVC-F 0.050 EC50 (nM) RVC-B 0.2 EC50 (nM) RSV Long RSV 9320 RSV 18357 EC50 (nM)
Slide 89: The power of optimizing small molecules
89 T H E P O W E R O F O P T I M I Z I N G S M A L L M O L E C U L E S RSV A2 Growth Inhibition RVC-D 0.013 EC50 (nM) RVC-E 0.093 EC50 (nM) RVC-F 0.050 EC50 (nM) RVC-B 0.2 EC50 (nM) RSV Long RSV 9320 RSV 18357 EC50 (nM) Next steps: single molecule cocktails with new SMs
Slide 90: DFCs could address unmet need in adult populations
90 D F C s C O U L D A D D R E S S A L A R G E U N M E T N E E D I N A D U L T P O P U L A T I O N S RSV FOR ADULTS, IV IS LIKELY THE ONLY OPTION WITH mAbs
Slide 91: Expanding outside of ID: RSV, HIV, SARS-CoV-2
91 RSV HIV SARS-CoV-2 Others — Improved potency — Broader coverage — Unique modality — Expanding outside of ID
Slide 92: HIV treatments are moving to long-acting drugs
92 H I V T R E AT M E N T S A R E M O V I N G TO LO N G - A C T I N G D R U G S DAILY ONE INJECTION PER MONTH1 1. Cabenuva package insert
Slide 93: HIV single molecule cocktail DFCs are highly potent
93 H I V S I N G L E M O L E C U L E C O C K T A I L D F C s A R E H I G H L Y P O T E N T SM CONJUGATE PEPTIDE FUSION DUAL HIV CONJUGATE HVC-A HVC-B2 HVC-C 1.. CEM-SS cells and HIV-1 IIIB live virus 2. CC50 > 10000 nM Optimized GP120 inhibitor conjugate Viral envelope binding peptide Single molecul
Slide 94: HIV DFCs have potent broad-spectrum activity
94 H I V D F C s H A V E P O T E N T B R O A D - S P E C T R U M A C T I V I T Y DUAL HIV CONJUGATE HVC-C TEMSAVIR CPE with hPBMCs - EC50 (nM) Single molecule cocktail CCR5 (UG/92/037) CXCR4/CCR5 (RW/92/009) CXCR4 (HT/92/599) CCR5 (US/921727) CCR5 (ZA/97/003) CXCR4/CCR5 (UG/92/001) MDR769 CXCR4/CCR5
Slide 95: Global strain coverage with HIV cocktail
95 G LO B A L S T R A I N C O V E R A G E W I T H S I N G L E M O L E C U L E H I V C O C K TA I L 1.. CEM-SS cells and HIV-1 IIIB live virus 2. CC50 > 10000 nM DUAL HIV CONJUGATE HVC-C 0.003 Single molecule cocktail Full activity in presence of human serum EC50 (nM)1 B B B C D AE A,C B,C B
Slide 96: Expanding outside of ID: RSV, HIV, SARS-CoV-2
96 RSV HIV SARS-CoV-2 Others — Superior potency — Broader coverage — Unique modality — Expanding outside of ID
Slide 97: Current treatments have growing limitations
97 C U R R E N T T R E AT M E N T S H AV E G R O W I N G L I M I TAT I O N S VACCINES Limited and waning coverage MONOCLONAL ANTIBODIES Poor tissue penetration Expensive Efficacy limited
Slide 98: SARS DFC program objective: pan-coronavirus activity
98 S A RS D F C P R O G R A M O B J E C T I V E : PA N - C O R O N AV I R U S A C T I V I T Y DFCs modularity enables: • Broader strain coverage • Targeting of multiple viruses
Slide 99: First generation single-target SARS DFC
99 1 s t G E N E R A T I O N S I N G L E - T A R G E T S A R S D F C * CC50 > 10000 nM (cytotoxicity measure, primate kidney cells) SVC-A* 29 EC50 (nM) Remdesivir ACTIVITY AGAINST CoV-OC43 147 EC50 (nM) NEXT GENERATION CORONAVIRUS DFCs • Testing DFCs with complimentary mechanisms to SVC-294 • Explor
Slide 100: Next steps: single molecule cocktails
100 FLU SARS RSV N E X T S T E P S : S I N G L E M O L E C U L E C O C K TA I L S TO TA R G E T M U LT I P L E R E S P I R ATO R Y V I R U S E S
Slide 101: Expanding to oncology: a single molecule cocktail
101 RSV HIV SARS-CoV-2 Oncology — Improved potency — Broader coverage — Unique modality — A single molecule cocktail
Slide 102: Oncology faces similar challenges to viral disease
102 O N C O L O G Y F A C E S S I M I L A R C H A L L E N G E S T O V I R A L D I S E A S E mAb/ADC LIMITATIONS • Toxicity/tolerability • Tissue/tumor penetration • Resistance/coverage • Expensive manufacturing SM LIMITATIONS • Toxicity/tolerability • Short half-life • Resistance
Slide 103: DFCs uniquely positioned to address these limitations
103 D F C s A R E U N I Q U E LY P O S I T I O N E D TO A D D R E S S T H E S E L I M I TAT I O N S Fc prolongs PK and improves tumor penetration over mAbs Small molecules fused to the Fc limit toxicity Multiple TMs enable a drug cocktail in a single molecule PENETRATION TOLERABILITY EFFICACY
Slide 104: Fc fragments have improved tumor penetration vs mAbs
104 Fc F R A G M E N T S H AV E I M P R O V E D T U M O R P E N E T R AT I O N V S m A b s 1. From Jäger et. al, https://doi.org/10.1021/acs.bioconjchem.1c00240 0 250µm MONOCLONAL ANTIBODY 150kDa 0 250µm Fc FRAGMENT1 50kDa Because DFCs are smaller, they should better penetrate tumors Bioconjugate Ch
Slide 105: DFCs combine best attributes of mAbs and small molecules
105 D F C s C O M B I N E T H E B E S T AT T R I B U T E S O F m A b s A N D S M A L L M O L E C U L E S Long Half-LifeShort Half-Life Low Tumor Penetration High Tumor Penetration Along with expected improvement in tumor penetration, DFCs extend half-life similar to mAbs DFCs Small molecules Monoclo
Slide 106: 1st generation DFCs equipotent in vitro to competitor molecules
106 1 S T G E N E R AT I O N D F C s : E Q U I P OT E N T I N - V I T R O TO C O M P E T I TO R M O L E C U L E S Discovery Preclinical IND-Enabling Phase 1 CBO−A IC50, (nM) CBO−B CBO−C CBO−D 2.6 2.6 1.2 4.7 SM DFC CONJUGATES Small Molecule IC50, (nM) 1.3 COMPETITOR PROGRAM All are structurally diff
Slide 107: 1st generation DFCs equipotent in vitro to competitor molecules
107 1 S T G E N E R A T I O N D F C s : E Q U I P O T E N T I N - V I T R O T O C O M P E T I T O R M O L E C U L E S Discovery Preclinical IND-Enabling Phase 1 CBO−A IC50, (nM) CBO−B CBO−C CBO−D 2.6 2.6 1.2 4.7 SM DFC CONJUGATES Small Molecule IC50, (nM) 1.3 COMPETITOR PROGRAM All are structurally
Slide 108: Cloudbreak DFCs are a new class of drugs
108 C L O U D B R E A K D F C s A R E A N E W C L A S S O F D R U G DFCs HAVE THE POTENTIAL to generate single molecule cocktails that can target multiple viruses or multiple pathways in oncology. 1. NEAR-TERM MILESTONES: IND filing CD388 (Influenza) at the end of 2021; initiation of Phase 1 trials
Slide 109: Summary
109 S U M M A R Y J E F F R E Y S T E I N , P h D C H I E F E X E C U T I V E O F F I C E R , C I D A R A
Slide 110: Cidara Investment Thesis
110 C I D A R A I N V E S T M E N T T H E S I S L e a d i n g s c i e n c e o n l o n g - a c t i n g p r e v e n t i o n s a n d t r e a t m e n t s REZAFUNGIN 1st antifungal in 15 years for treatment and prophylaxis indications Treatment – Phase 3 Prophylaxis – Phase 3 Validated with Deal ReSTORE